Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Free Report) and Revolution Medicines (NASDAQ:RVMD – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
Risk & Volatility
Fresh Tracks Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.
Institutional and Insider Ownership
25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by company insiders. Comparatively, 8.0% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Revolution Medicines | 0 | 0 | 10 | 1 | 3.09 |
Revolution Medicines has a consensus target price of $54.00, indicating a potential upside of 14.29%. Given Revolution Medicines’ higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Fresh Tracks Therapeutics.
Profitability
This table compares Fresh Tracks Therapeutics and Revolution Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | N/A | N/A | N/A |
| Revolution Medicines | N/A | -34.57% | -30.71% |
Valuation & Earnings
This table compares Fresh Tracks Therapeutics and Revolution Medicines”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $8.01 million | 0.53 | -$5.69 million | ($1.41) | -0.50 |
| Revolution Medicines | $11.58 million | 681.58 | -$436.37 million | ($3.64) | -12.98 |
Fresh Tracks Therapeutics has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Revolution Medicines beats Fresh Tracks Therapeutics on 8 of the 13 factors compared between the two stocks.
About Fresh Tracks Therapeutics
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
